Today in healthtech: TranQool reaches 1.3 million Canadians after acquisition, Optina Diagnostics partners with Imagia


Several healthtech companies have made announcements on the growth of their firms, announcing new partnerships and key milestones. Here’s the latest on these company updates.

HumanaCare reaches 1.3 million customers through TranQool acquisition

Employee health provider HumanaCare announced that it has provided access to therapy for 1.3 million Canadians after acquiring TranQool.

HumanaCare announced that it acquired Toronto-based virtual therapy platform TranQool in May 2018, including its technology and brand. HumanaCare members are able to chat and get video access to counselling and therapy services,

“HumanaCare is continuing to develop our capabilities to expand access to virtual care services in areas such as disability management, medical second opinion, caregiver support, healthcare navigation, and chronic disease management services,” said Jamie Marcellus, president of HumanaCare. “Our customers have embraced our focus on innovation, outcomes and service experience and our continued focus will support our position as a Canadian leader in organizational health services.”

Optina Diagnostics partners with Imagia to develop biomarkers for Alzheimer’s

Optina Diagnostics, which is developing technology for the early detection of Alzheimer’s, is partnering with Imagia.

Imagia is building out an AI for medical imaging to help detect diseases. Through the partnership, the companies will develop retinal biomarkers for Alzheimer’s disease, by leveraging spectral retinal images combined with deep learning architectures.

“The opportunity to work closely with the experts at Imagia Cybernectics on the discovery of spectral biomarkers for early stage, low cost, non-invasive diagnostics of Alzheimer’s disease is extremely motivating,” said David Lapointe, CEO at Optina Diagnostics.

“This collaboration aligns with Imagia’s initiative in preventative health,” said Florent Chandelier, CTO at Imagia. “Leveraging our deep radiomics platform, we aim at discovering actionable imaging biomarkers from Optina’s unique spectral retinal imaging, to improve Alzheimer’s patient management.”

Jessica Galang

Jessica Galang

Freelance tech writer. Former BetaKit News Editor.

0 replies on “Today in healthtech: TranQool reaches 1.3 million Canadians after acquisition, Optina Diagnostics partners with Imagia”